Challenges in pharmacogenetics

Eur J Clin Pharmacol. 2013 May:69 Suppl 1:17-23. doi: 10.1007/s00228-013-1492-x. Epub 2013 May 3.

Abstract

The attempt to optimize drug treatment of patients by using evidenced-based medicine considering individual physiological and disease-related conditions is standard of modern medicine. Pharmacogenetics (PGx) has contributed to individualization considering hereditary genetic information; however, increasingly, pharmacogenomics is becoming essential, particularly in relation to modern oncology. New technologies such as next-generation sequencing and rapid development of computational and information sciences will help to better elucidate the consequences of genetic variation, considering also epigenetics and gene-environmental interactions and their translation into clinically relevant individual phenotypes. This review highlights the current challenging and most promising examples of PGx.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Humans
  • Neoplasms / drug therapy
  • Organ Transplantation
  • Pain / drug therapy
  • Pharmacogenetics*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Precision Medicine

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors